Listen to dermatologist and National Psoriasis Foundation Board member, Jerry Bagel, M.D., Director of the Psoriasis Treatment Center of New Jersey, share guidance for older adults on how to manage their moderate-to-severe plaque psoriasis symptoms, provide an overview of ILUMYA® (tildrakizumab-asmn) as a treatment option and discuss how to navigate treatment coverage under Medicare Part B. We will also hear from Nancy about her journey with moderate-to-severe plaque psoriasis.
ILUMYA® is a prescription medicine used to treat adults with moderate to severe plaque psoriasis who may benefit from taking injections, pills (systemic therapy), or phototherapy. The most common (≥1%) adverse reactions for ILUMYA® compared to placebo are upper respiratory infections (14% vs 12%), injection-site reactions (3% vs 2%), and diarrhea (2% vs 1%). These are not all of the possible side effects of ILUMYA®. Call your doctor for medical advice about side effects.
This webinar is sponsored by Sun Pharma. For Important Safety Information: https://bit.ly/2We7fIS.
Contact Bev Bromfield, Outreach Manager, at bbromfield@psoriasis.org or 800-723-9166, ext. 362.
The views and opinions expressed in the webinars are those of the speakers. The speakers' views and opinions are not endorsed by the National Psoriasis Foundation or its sponsors.
We use cookies to offer you a better experience and analyze our site traffic. By continuing to use this website, you consent to the use of cookies in accordance with our Privacy Policy.
